Organization (Industry)
Anika Therapeutics, Inc.
ClinicalTrials.gov lists Anika Therapeutics, Inc. as lead sponsor of 17 trials. It has 10 active development programs and 2 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Anika Therapeutics, Inc.: 17 lead-sponsored trials and 1 legal-entity registration.
Disease areas (6)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Osteoarthritis | 11 |
| Osteoarthritis, Knee | 5 |
| Osteoarthritis, Hip | 3 |
| Tendinopathy | 2 |
| Tennis Elbow | 2 |
Showing 5 of 6 disease areas.
Trials by start year as sponsor or collaborator (10)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 2 |
| 2024 | 1 |
| 2021 | 3 |
| 2020 | 2 |
| 2019 | 4 |
| 2017 | 2 |
| 2015 | 2 |
| 2013 | 1 |
| 2009 | 1 |
| 2008 | 1 |
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (10)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Cingal | Osteoarthritis | Phase 3 | 7 |
| Cingal | Osteoarthritis, Knee | Phase 3 | 4 |
| Monovisc | Osteoarthritis | Phase 3 | 4 |
| Triamcinolone Hexacetonide | Osteoarthritis, Knee | Phase 3 | 3 |
| Triamcinolone Hexacetonide | Osteoarthritis | Phase 3 | 3 |
Showing 5 of 10 active programs.
Approved assets (2)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Triamcinolone Hexacetonide | 3 |
| HYALURONIC ACID | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 83% hit target (n=12) | 40% on time (n=10) |
Journals published in (6)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Cartilage | 1 |
| Cutis | 1 |
| Dermatologica | 1 |
| JBJS reviews | 1 |
| Lasers in medical science | 1 |
Showing 5 of 6 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 25 | 6 | 2025-09-16 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 112,819,000 | -10,880,000 | 25,770,000 |
| 2024 | 119,907,000 | -56,385,000 | 25,544,000 |
| 2023 | 120,792,000 | -82,667,000 | 21,763,000 |
| 2022 | 113,827,000 | -14,859,000 | 18,321,000 |
| 2021 | 147,794,000 | 4,134,000 | 27,327,000 |
| 2020 | 130,457,000 | -23,982,000 | 23,431,000 |
| 2019 | 114,610,000 | 27,193,000 | 16,665,000 |
| 2018 | 105,555,000 | 18,722,000 | 18,190,000 |
| 2017 | 113,420,000 | 31,816,000 | 18,787,000 |
| 2016 | 103,379,000 | 32,547,000 | 10,732,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (13)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-07-10 | Debt financing | not disclosed | Sec extracted |
| 2025-03-07 | Other financing | 4,500,000 | Sec extracted |
| 2024-10-31 | Other financing | not disclosed | Sec extracted |
| 2024-10-31 | Other financing | not disclosed | Sec extracted |
| 2024-05-28 | Other financing | not disclosed | Sec extracted |
Showing 5 of 13 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 11 |
FDA recalls (1)
| Product | Classification | Initiated |
|---|---|---|
| Hyalomatrix, Product nos. 651105, 651103, 651104, and 651301 Product Usage: Hyalomatrix is a bi-layered, sterile, flexible, and comfortable wound dressing that acts as an advanced wound care device. It is comprised of a non-woven pad entirely composed of HY AFF 11, a benzyl ester of hyaluronic acid, and a semipermeable silicone membrane, which controls water vapor loss, provides a flexible covering for the wound surface, and adds increased tear strength to the device. The HYAFFl 1 wound contact layer biodegradable matrix acts as a scaffold for cellular invasion and capillary growth. Hyalomatrix is indicated for the management of wounds including: partial and full-thickness wounds; second-degree bums; pressure ulcers; venous ulcers; diabetic ulcers; chronic vascular ulcers; tunneled/undetermined wounds; surgical wounds (donor sites/grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence); trauma wounds (abrasions, lacerations, skin tears); and draining wounds. The device is intended for one-time use. | Class II | 2018-05-10 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 11 | 2025-11-21 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| ANIKA THERAPEUTICS, INC. | Bedford, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Latest dated events (80)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-07-10 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-04-13 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-01-22 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2025-11-21 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2025-09-16 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 80 events.
Biomarker capability evidence (6)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| F2 | Trial sponsor | Named in trial exclusion criteria |
| F3 | Trial sponsor | Named in trial exclusion criteria |
| SERPINB6 | Trial sponsor | Named in trial exclusion criteria |
| F2 | Trial sponsor | Mentioned in trial text |
| F3 | Trial sponsor | Mentioned in trial text |
Showing 5 of 6 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, fda warning letters, fda untitled letters, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.